Sign up to save your podcasts
Or
Share Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Featuring an interview with Dr Lindsey Roeker, including the following topics:
- Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00)
- Safety of BTK inhibitors in older and frail patients with CLL (3:41)
- Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20)
- Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32)
- Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31)
- Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16)
- Sequencing, tolerability and future development involving pirtobrutinib (25:57)
- Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28)
- Clinical considerations in the management of Richter's transformation (38:14)
- Survival outcomes and quality of life for patients with CLL (41:02)
- Ongoing and future efforts to improve CLL treatment outcomes (45:01)
CME information and select publications
View all episodes
By Dr Neil Love
4.6
112112 ratings
Featuring an interview with Dr Lindsey Roeker, including the following topics:
- Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00)
- Safety of BTK inhibitors in older and frail patients with CLL (3:41)
- Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20)
- Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32)
- Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31)
- Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16)
- Sequencing, tolerability and future development involving pirtobrutinib (25:57)
- Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28)
- Clinical considerations in the management of Richter's transformation (38:14)
- Survival outcomes and quality of life for patients with CLL (41:02)
- Ongoing and future efforts to improve CLL treatment outcomes (45:01)
CME information and select publications
More shows like Research To Practice | Oncology Videos
View all
JAMA Editors' Summary
136 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
496 Listeners
Breast Cancer Update
69 Listeners
Lung Cancer Update
30 Listeners
Hematologic Oncology Update
76 Listeners
Prostate Cancer Update
13 Listeners
Gastrointestinal Cancer Update
17 Listeners
Gynecologic Oncology Update
13 Listeners
Dermatologic Oncology Update
0 Listeners
ASCO Daily News
57 Listeners
White Coat Investor Podcast
2,442 Listeners
The Curbsiders Internal Medicine Podcast
3,342 Listeners
Core IM | Internal Medicine Podcast
1,155 Listeners
The ONS Podcast
198 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
365 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Two Onc Docs
188 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners
Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing
0 Listeners